ClinicalTrials.Veeva

Menu
A

Alliance Clinical Research of Tampa | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Vedolizumab
LY3041658
Mirikizumab
PF-06480605
Ustekinumab
PF-06700841
IMG-007
GLPG3667
Tofacitinib
Lutikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 14 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moder...

Enrolling
Ulcerative Colitis
Drug: Tofacitinib
Drug: Vedolizumab

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Active, not recruiting
Alopecia Areata (AA)
Drug: IMG-007

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with...

Enrolling
Ulcerative Colitis
Biological: ALTB-268

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get...

Enrolling
Ulcerative Colitis Flare
Ulcerative
Drug: PL8177 Placebo
Drug: PL8177

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermati...

Active, not recruiting
Atopic Dermatitis
Skin Diseases
Drug: Orismilast modified release tablets
Drug: Placebo

Trial sponsors

Lilly logo
Pfizer logo
Takeda logo
AbbVie logo
A
A
G
I
P
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems